RTX ( DrugBank: - )

5 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
11	重症筋無力症	1
46	悪性関節リウマチ	7
65	原発性免疫不全症候群	1
222	一次性ネフローゼ症候群	2
240	フェニルケトン尿症	1

11. 重症筋無力症

臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900024644	2019-07-30	2019-07-19	Investigation of the clinical heterogeneity of childhood onset myasthenia gravis in China	Investigation of mechanism of clinical heterogeneity of childhood onset myasthenia gravis and precis ...	maysthenia gravis	routine group:routine therapy;FK506 group:routine+FK506 therapy;RTXgroup:routine+RTXtherapy;Thymecto ...	Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and ...	NULL	Pending			Both	routine group:20;FK506 group:20;RTX group:20;Thymectomy group:20;FK506+Thymectomy group:20;RTX+Thymectomy group:20;	N/A	China

First Previous1Next Last

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-000710-42-NL (EUCTR)	15/03/2021	08/03/2021	Research into the effect of the COVID-vaccine in patients who are treated with rituximab (RTX-COVAC ...	The RTX-COVAC study: humoral response to COVID-19 vaccination after rituximab, and relation with dos ...	Rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: Comirnaty Trade Name: COVID-19 Vaccine Moderna Product Name: COVID-19 Vaccine Moderna Trade ...	Sint Maartenskliniek	NULL	Not Recruiting			Female: yes Male: yes	270	Phase 4	Netherlands
2	EUCTR2020-002507-19-NL (EUCTR)	07/09/2020	03/09/2020	Research into administration of lower dosed rituximab with an injection	Comparison of subcutaneous and intravenous continued treatment with ultra-low dose Rituximab in rheu ...	rheumatoid arthritis MedDRA version: 21.0;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Trade Name: MabThera Product Name: rituximab Trade Name: Rixathon Product Name: rituximab	Sint Maartenskliniek	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	36	Phase 4	Netherlands
3	NCT05116228 (ClinicalTrials.gov)	September 1, 2015	21/3/2018	Non-inferiority of Reduced-dose Rituximab in Rheumatoid Arthritis in Low Disease Activity and Remiss ...	Randomized, Prospective, Active-comparator Controlled, Patient-blinded Study to Demonstrate Non-infe ...	Rheumatoid Arthritis;Remission	Drug: 500mg RTX Group;Drug: 1000mg RTX Group	Medical University of Vienna	NULL	Terminated	18 Years	N/A	All	21	Phase 4	Austria
4	NCT01332994 (ClinicalTrials.gov)	March 2011	18/3/2011	A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed ...	Efficacy and Safety Study of a Sequential Therapy of Tocilizumab (TCZ) and, if Initially Inadequatel ...	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	519	Phase 3	Germany
5	EUCTR2010-022049-88-DE (EUCTR)	05/01/2011	11/11/2010	Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quate ...	Efficacy and safety study of a sequential therapy of tocilizumab (TCZ) and, if initially inade-quate ...	Rheumatoid Arthritis (RA) MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumato ...	Trade Name: RoActemra 20 mg/ml Concentrate for solution for infusion Product Name: Tocilizumab Product ...	Roche Pharma AG	NULL	Not Recruiting			Female: yes Male: yes			Germany
6	NCT02731560 (ClinicalTrials.gov)	January 2010	6/3/2016	Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pa ...	Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Drug: Rituximab	Prof. Abid Z. Farooqi	Aga Khan University;Fatima Memorial Hospital;Fauji Foundation Hospital, Rawalpindi	Completed	18 Years	80 Years	Both	74	Phase 4	NULL
7	EUCTR2006-005386-19-BE (EUCTR)	19/12/2006	03/11/2006	Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthr ...	Cytokines and inflammatory proteins gene expression study in synovial biopsies from rheumatoid arthr ...	Rheumatoid arthritis refractory to TNF blockers patients MedDRA version: 8.1;Level: LLT;Classificati ...	Trade Name: MabThera	Cliniques Universitaires Saint-Luc	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 4	Belgium

First Previous1Next Last

先頭へ

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02789397 (ClinicalTrials.gov)	May 2, 2016	16/5/2016	Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variabl ...	Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatou ...	Granulomatous and Lymphocytic Interstitial Lung Disease	Drug: Rituximab (RTX) and Azathioprine (AZA);Drug: Placebos	Medical College of Wisconsin	NULL	Withdrawn	18 Years	N/A	All	0	Phase 2	NULL

First Previous1Next Last

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100042674	2021-01-18	2021-01-26	Standard dose Rituximab for membranous nephropathy: a multi-center prospective cohort study	Standard dose Rituximab for membranous nephropathy: a multi-center prospective cohort study	syndrome disease	experimental group:RTX treatment;	Jiangsu Province People's Hospital	NULL	Recruiting	18	75	Male	experimental group:65;	Phase 4	China
2	ChiCTR-IPR-16008527	2016-06-01	2016-05-24	Rituximab in the treatment of refractory membranous nephropathy: a multicenter, randomized, controll ...	Rituximab in the treatment of resistant membranous nephropathy: a multicenter, randomized, controlle ...	Membranous nephropathy	CsA group:oral CsA and glucosteroid;RTXgroup:intravenous RTX;CTX:Intravenous cyclophosphamide and gl ...	Ruijin Hospital, affiliated to Shanghai Jiaotong University, School of medicine	NULL	Completed	18	70	Both	CsA group:60;RTX group:60;CTX:60;	Phase 4	China

First Previous1Next Last

240. フェニルケトン尿症

臨床試験数 : 143 / 薬物数 : 90 - (DrugBank : 10) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 5

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04110496 (ClinicalTrials.gov)	January 29, 2020	23/9/2019	Safety and Tolerability of RTX-134 in Adults With Phenylketonuria	A Phase 1b Open-Label Single Dose Safety, Tolerability, and Pharmacokinetics Study of RTX-134 in Adu ...	Phenylketonurias	Drug: RTX-134	Rubius Therapeutics	NULL	Terminated	18 Years	N/A	All	1	Phase 1	United States

First Previous1Next Last

先頭へ